Tate & Lyle (LSE:TATE) long ago stopped being a sugar company. Today it is a maker of speciality ingredients that help food and drink firms cut sugar, calories and fat while keeping products tasting good, a Business riding the global push towards healthier eating. That very appeal has now attracted a takeover.
Its full-year results, published on 21 May 2026, came alongside a recommended offer from a larger US rival.
A speciality-ingredients business
Tate & Lyle develops ingredients across three areas: sweetening, which includes reduced-sugar and stevia-based solutions; mouthfeel, the texturants and fibres that give low-fat or low-sugar products their body; and fortification. It serves beverages, dairy, bakery and snacks makers worldwide, with roughly 5,000 employees across 37 countries.
The strategy has been to become a solutions partner, helping customers reformulate recipes as regulators and consumers turn against sugar. Its 2024 Acquisition of CP Kelco, a speciality-gums and texturants business, was designed to strengthen that hand in the fast-growing mouthfeel market.
The Ingredion approach caps a long transformation. Tate & Lyle sold its origins, the bulk-sweetener and primary-products business, years ago to focus on higher-margin speciality ingredients, betting that the future lay in helping food companies reformulate rather than in Commodity sweeteners. That bet made it both a growth story and, ultimately, an attractive acquisition.
For Ingredion, buying Tate & Lyle brings scale, complementary technology and a stronger position in the mouthfeel and sweetening niches that both companies chase. Combining two leaders in a specialised field is exactly the sort of deal that can generate synergies, but also the sort that regulators examine closely for its effect on customer choice.
Steady results and a Takeover offer
For the year to 31 March 2026, Revenue fell about 3% on a pro-forma basis amid muted demand, and adjusted EBITDA also slipped 3%, with the Margin easing 30 basis points to 20.7%. The Dividend was held at 19.8p, net Debt was £939m, or 2.3 times earnings, and CP Kelco cost synergies of $24m were delivered ahead of schedule.
The dominant news, however, was corporate. Alongside the results, the US ingredients group Ingredion made a recommended all-cash offer of 595p per share, valuing Tate & Lyle's Equity at around £2.7bn. The board recommended the deal, which would combine two of the industry's leading speciality-ingredients players.
The risks and the bigger picture
For now the takeover dominates the Investment case, pinning the share price to the offer and shifting attention to regulatory clearance and Shareholder approval. Deals of this size in the food-ingredients sector can attract competition scrutiny, so completion is not a formality.
The underlying business faces its own challenges: soft consumer demand, the task of fully integrating CP Kelco, and margin pressure from input costs. The long-term driver, the shift to healthier, lower-sugar food, remains intact, but it has not immunised Tate & Lyle from a difficult Demand backdrop.
What to watch next
Investors should watch the progress of the Ingredion offer through regulatory and shareholder approvals, any counter-bid, and, should the deal falter, the pace of the CP Kelco integration and the recovery in demand. The dividend and net debt matter more if the company stays independent.
Tate & Lyle (LSE:TATE) has reinvented itself around the enduring trend towards eating less sugar, and that reinvention has made it a target rather than merely a survivor. If the Ingredion deal completes, shareholders will receive cash for a business whose strategic value a larger rival was willing to pay up to secure. For shareholders the decision is now less about sugar itself and more about certainty: accept Ingredion's cash offer and step away, or hope a rival ultimately bids higher for a business that the healthier-eating trend made too attractive for a rival to ignore.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...